Specialty Pharmacy

Top stories of the week on Specialty Pharmacy Times from July 6 to July 10.

Less than 1% of healthy patients enrolled in early-stage clinical trials experience serious adverse events, half of which are unrelated to the drug or procedure studied, a new meta-analysis suggests.

Premature aging of the lung cells plays a factor in pathogenesis.

Lower inflammation scores found in patients with RA receiving statins.

Pharmacy was charged with overbilling hemophilia patients.

Charitable drug distributors are improving access to essential medications for low-income, uninsured patients in the United States.

Exchange plan spending on hepatitis C drugs increased 96% in the first quarter of 2015.

Ron Lanton III, Esq, president of True North Political Solutions, LLC, discusses how specialty pharmacy has been affected by HIPAA laws.

Preliminary evidence suggests that the first-generation antihistamines chlorcyclizine and hydroxyzine may fight HCV infection for pennies a day.

Discovery may lead to cost effective treatment options.

Review the clinical data behind the FDA's approval of the combination drug Orkambi (lumacaftor/ivacaftor) for select patients with cystic fibrosis.

Access is open to US adult patients who are refractory to the most common anti-myeloma drug classes.

Complete protection seen in half of non-human primates vaccinated against repeated challenges with simian immunodeficiency virus.

Xeljanz treat adults with moderate to severe active RA who have had an inadequate response or intolerance to methotrexate.

MM41 targets cell nuclei to provide a new method of attacking pancreatic cancer.

Nivolumab and ipilmumab help immune system to shrink tumors.

Fiona Smythe, vice president of strategy at mscripts, discusses developing trends in mobile health care applications.

Restoration of miR-29 in cancer stromal cells helped decrease cancer growth.

Tumor suppressing molecule that prevents growth could lead to personalized therapy.

Treatment could make existing cancer drugs more effective.

Drug decreases enthesitis and dactylitis by blocking the production of cytokines that promote inflammation.

Gilead Sciences is seeking FDA approval for its third tenofovir alafenamide-based HIV treatment.

Hydrogel prevents drugs from prematurely leaving the body.

Top stories of the week on Specialty Pharmacy Times from June 29 through July 3.

Lung function and health status decreases across all levels of severity.

The impact of products such as orange juice on melanoma.

Patients face significant financial burdens from treatment.

CEO of Avella Specialty Pharmacy Rebecca M. Shanahan, Esq., discusses how specialty pharmacies can best manage the rising cost of specialty drugs to improve outcomes for patients.